menu
    • menu
    [{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hong Kong \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"University of Hong Kong \/ Undisclosed"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ribavirin","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brii Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Vir Biotechnology"},{"orgOrder":0,"company":"Irrua Specialist Teaching Hospital","sponsor":"Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NIGERIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Irrua Specialist Teaching Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irrua Specialist Teaching Hospital \/ Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme","highestDevelopmentStatusID":"9","companyTruncated":"Irrua Specialist Teaching Hospital \/ Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Scientific and Technological Research Council of Turkey","sponsor":"Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Scientific and Technological Research Council of Turkey","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Scientific and Technological Research Council of Turkey \/ Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO","highestDevelopmentStatusID":"9","companyTruncated":"Scientific and Technological Research Council of Turkey \/ Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO"}]

    Find Clinical Drug Pipeline Developments & Deals for Ribavirin

    Menu

    Ribavirin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Irrua Specialist Teaching Hospital

                            Country arrow
                            FNCE
                            Not Confirmed

                            Irrua Specialist Teaching Hospital

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | Médecins Sans Frontières Belgium | Alex Ekwueme

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

                            Details : Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Lassa Fever.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2024

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | Médecins Sans Frontières Belgium | Alex Ekwueme

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Brii Biosciences

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Brii Biosciences

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Vir Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV ...

                            Details : Peginterferon is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 01, 2023

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Vir Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy V...

                            Details : Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 08, 2022

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Scientific and Technological Research Council of Turkey

                            Country arrow
                            FNCE
                            Not Confirmed

                            Scientific and Technological Research Council of Turkey

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Koç University | Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

                            Details : Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 02, 2021

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Koç University | Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory ...

                            Details : Virazole (Ribavirin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Virazole

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 16, 2020

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of Hong Kong

                            Country arrow
                            FNCE
                            Not Confirmed

                            University of Hong Kong

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lopinavir,Ribavirin,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Triple Drug Combination Shows Promise in Covid-19 Treatment

                            Details : Trial revealed that patients treated with triple drug combination (lopinavir–ritonavir and ribavirin) tested negative for COVID-19 five days earlier than those treated with lopinavir–ritonavir alone.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2020

                            Lead Product(s) : Lopinavir,Ribavirin,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory ...

                            Details : Virazole (Ribavirin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Virazole

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 22, 2020

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bausch Health Begins Clinical Study in Canada Evaluating Virazole in Combo with Standard of Care Therapy for C...

                            Details : The company believes that since ribavirin is a synthetic nucleoside, It may work to stop viral replication and VIRAZOLE may be effective in reducing the severity of COVID-19 infection.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : Ribavirin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth